Stem cell treatments could come by 2005

韩雪娜

日期: 2002-10-25 今日/总浏览: 1/15626 d% p6 {9 ~9 u' R5 @& ?5 e
) ~2 r: F8 L  w4 o
# q% _+ F5 b3 @0 v# v

, a. \$ ?8 l8 F" V; @. g% e7 i
! u+ P& g1 d( X: V2 `Thefirstcommerciallyavailablestemcell-derivedproductslikelywillcomefromadultstemcellsandbeforthetreatmentofneurologicaldisorderssuchasParkinson'sandAlzheimer'sdisease,theheadofanadultstemcellcompanytoldUnitedPressInternational.
, ^# [' s5 x( gTheproductscouldbeavailableinthenextthreeyears,saidMartinMcGlynn,presidentandchiefexecutiveofficerofStemCellsInc.,ofPaloAlto,Calif.,whichisworkingtodevelopmedicaltreatmentsderivedfromadultstemcells.McGlynnwasexpectedtomakesimilarremarksatTechvest's4thAnnualHealthcareConference&ExpoinBostonWednesday.
7 W8 h. I4 N$ _Stemcellshavetheabilitytogiverisetodifferentcelltypesinthebody.Theyhavethepotentialtoreplacetissuesdamagedbydisease.
! w2 Y$ ~2 e+ n2 E+ w/ oEmbryonicstemcellscangiverisetoanycelltypeandthushavethegreatestpotentialtotreatthewidestrangeofdiseases.However,theyarecontroversialbecauseharvestingthemrequiresthedestructionofembryos.Adultstemcells,whichcanbederivedfromadulttissueswithoutharmingthedonor,offeralesscontroversialalternative,althoughtheycangiveriseonlytoalimitednumberofcelltypes.
* L" t3 B& e) ?+ }5 p5 J" YMypredictionisthat...we'relikelytoseeoneortwostemcellproductsonthemarketinthisdecade,McGlynnsaid.Productsderivedfromadultstemcellsarelikelytobethefirstproductsbecausethesearefurtheralonginthedevelopmentprocessanddon'thavealltheregulatoryhurdlesthatareassociatedwithembryonicstemcells,hesaid.1 D( n8 W( j3 F0 D
Suchproductsprobablywillappearonthemarketstartingfromaround2005andcontinuinginthebackhalfofthisdecade,hesaid.  y) ?2 l  K- \& y. l' v
McGlynnpredictedthefirstproductswouldbetreatmentsfordegenerativediseasesofthecentralnervoussystem,includingParkinson's,Alzheimer's,strokeandparalysis.5 j: z; P( D) w+ q2 f, Y# M) J
Iwouldagreewith(McGlynn)thatsomeoftheearliestproductstoreachcommercializationwillbeforneurologicaldisorders,LindaPowers,managingdirectorofToucanCapital,aventurecapitalfirminBethesda,Md.,toldUPI.It'sstillupintheairwhether(thefirstproducts)willbeadultorembryonicstemcells,addedPowers,whosefirmhasmadeinvestmentsinbothadultandembryonicstemcellcompanies.( F  S& {. }9 ]. A
Wereallyarelookingacrosstheboardatadultandembryonicstemcells,Powerssaid.We'renottiltingonewayortheother.Wewanttoseewhatlookslikeitproducesthebestresultsandgofromthere.It'stooearlytotellwhichlineofcellswillbethefirsttoreachthemarket,sheadded.
# N5 a! k  x  k! Y' {/ A. xMcGlynnsaidheexpectsembryonicstemcellseventuallytobecommercializedaswell.Subjecttotheavailabilityofcapital,Iwouldanticipateembryonicstemcellsciencewillcontinuetobeworkedonandimproved,hesaid.Overtime,scientistsmightlearnhowtofullyunlockthepotentialofembryonicstemcellsanddevelopthemasdiseasetreatments,hesaid.- T% i+ h1 _3 q" k* D4 k
Dependingoneconomicsandthedisease-treatingcapabilityofeachcellline,McGlynnadded,Wecouldhaveboth(adultandembryonicstemcell-derivedproducts)outthereonthemarket.
4 Q0 K5 ^- f6 s& O& H8 |; a6 ?$ z* @7 B

( I2 a( y5 R& P2 Z1 Q2 }2 X( v# z# e2 B  D3 Y- g, }

% K; \6 X) y9 |& |# h
  E" p1 _4 L' C5 \+ b( o: z* o, @作者: Steve Mitchell! P, Q8 \* U: J
来源: UPI Medical Correspondent
: i2 Y0 P/ V, J. L' a9 r发布者: 刘斌